| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Trinity Biotech plc$11.6
-1.15 (-9.02%)
F 10Pipeline Score MedTech · Clinical
Market Cap
11.64 M
EPS
-2.02
P/E Ratio
-
Value Trade
96.35 K
3.79 %
Week
-12.75 %
1 Month
-18.1 %
3 Month
-32.28 %
6 Month
-96.34 %
5 Year
-99.31 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
13.45 K
52 Week Range
0.50 - 3.44
% held by Insiders
-
% held by Institutions
6.36 %
Enterprise Value
144.49 M
Total Shares
19.34 M
Short %
-
Float Shares
18.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trinity Biotech plc
5Total events
2Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1NDA Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsCGMFiledClinical Data
Subscribe to view catalyst details
TBD
◆ATM ProgramCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 841 of 913)
Percentile RankTrinity Biotech plc has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CGM+ | diabetes management | — | 2026-07-02 | over 5,000 hours of clinical wear data | New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring Read More | |
CGM+ | diabetes management | — | 2026-07-02 | over 5,000 hours of clinical wear data | New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring Read More | |
CGM+ | diabetes management | — | 2026-07-02 | over 5,000 hours of clinical wear data | New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRIB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TRIB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TRIB▼ -15.4%on this news
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
Trinity Biotech has partnered with Latch Medical to advance biosensor-guided precision drug delivery solutions. This collaboration combines Trinity's CGM+ wearable biosensor platform with Latch's intradermal drug delivery technology to develop innovative therapies for metabolic conditions. The partnership aims to create personalized treatment approaches leveraging real-time metabolic data.
Read more →TRIB▲ +5.5%on this news
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech announced positive clinical trial results for its CGM+ wearable biosensor, which effectively distinguishes between true and false low glucose readings. The technology addresses a common limitation in conventional continuous glucose monitoring systems, providing additional physiological context. This advancement is expected to enhance user experience and strengthen Trinity's market position in the $15 billion global CGM market.
Read more →TRIB▼ -6.9%on this newsshared move
Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
Trinity Biotech's subsidiary, Trinovium, has secured Silver Membership in the Open Compute Project, marking a significant milestone in its entry into the AI data center market. This membership will facilitate engagement with industry leaders and support the development of advanced liquid cooling solutions. The liquid cooling market is expected to grow substantially, providing Trinovium with opportunities for product validation and customer access.
Read more →TRIB▲ +15.9%on this newsshared move
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
Trinity Biotech has announced the termination of its Standby Equity Purchase Agreement with Yorkville Advisors. The decision reflects the company's current financing strategy, indicating a shift away from utilizing the equity line of credit facility. The announcement includes forward-looking statements regarding the company's financial resources and potential growth, amidst various operational risks.
Read more →TRIB▼ -39%on this news
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
Trinity Biotech has launched Trinovium, a subsidiary focused on advanced liquid cooling solutions for AI data centers. This initiative aims to address the growing need for reliable cooling systems as AI workloads increase. The liquid cooling market is expected to grow significantly, providing Trinity with a capital-efficient entry into this expanding sector. The company will utilize its existing manufacturing capabilities to support Trinovium's operations.
Read more →TRIB▼ -15.8%on this news
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
Trinity Biotech has received substantial orders for over 2 million TrinScreen HIV tests, reinforcing demand in global health markets. The company reported a 43% revenue increase in Q1 2026, with significant improvements in gross margin. Despite a net loss, the company is executing its Comprehensive Transformation Plan to enhance profitability and scalability.
Read more →TRIB▼ -15.8%on this newsshared move
Trinity Biotech plc Paul Murphy (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech Awarded Significant Orders for Over 2 Million
Trinity Biotech plc has announced the receipt of significant orders for over 2 million TrinScreen HIV tests, demonstrating renewed demand in global health markets. The company also reported a 43% increase in revenue for Q1 2026, along with improvements in gross margin. However, Trinity Biotech reported a net loss of $4.4 million and continues to face regulatory challenges and potential funding disruptions. The fulfillment of these orders is expected to significantly contribute to the company’s revenue goals in 2026.
Read more →TRIBTrinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
Trinity Biotech announced the appointment of Jerry Lydon as Head of North America Commercial Operations, aiming to enhance revenue and profitability. His experience in diagnostics will aid in strengthening commercial execution and overseeing new product developments. The company highlighted ongoing progress in its Comprehensive Transformation Plan, noting improvements in gross margins and production scaling. However, challenges remain with an increased net loss and declining revenues, attributed to global health funding disruptions.
Read more →TRIBTrinity Biotech plc Paul Murphy (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech Appoints Jerry Lydon to Lead North America Co
Trinity Biotech plc has appointed Jerry Lydon as the new lead for North America Commercial Operations, aiming to strengthen its revenue and profitability following a Comprehensive Transformation Plan. The company reported its Q4 2025 financial results, revealing revenue in line with prior forecasts but also a decrease compared to the previous year due to various operational challenges. Despite a few improvements, including better gross margins and the recognition of its Premier HbA1c 9210 platform, the company faces financial hurdles, indicated by increased net losses and declining revenues.
Read more →TRIB▼ -5.1%on this news
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
Trinity Biotech announced successful clinical results for its enhanced EpiCapture prostate cancer test, which uses machine learning to improve risk prediction accuracy. The test demonstrated an impressive clinical accuracy of 85% in a study involving 750 diverse patient samples. The company plans to commercialize the test through its New York laboratory, marking a significant step into precision oncology.
Read more →TRIB▼ -7%on this news· ran to -19% by day 3shared move
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
Trinity Biotech has partnered with the University at Buffalo to develop and commercialize biomarkers for Sjögren's Syndrome, a commonly underdiagnosed autoimmune disease. This collaboration aims to enhance diagnostic accuracy and speed, addressing significant unmet clinical needs. The initiative is part of Trinity's strategy to expand its specialty diagnostic offerings in the U.S. market.
Read more →TRIB▲ +10.6%on this newsshared move
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Trinity Biotech has initiated the commercial rollout of its next-generation HbA1c column system in Brazil after receiving regulatory approval. The Premier Hb9210 platform, now the only HbA1c system to achieve IFCC Gold classification for 2026, aims to enhance diabetes management in a country with a large diabetes population. The company has also appointed Bruna Gigliotti to lead its Brazilian operations, anticipating increased adoption of the new system.
Read more →TRIB▲ +10%on this news· ran to +24% by day 3shared move
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
Trinity Biotech plc announced that its senior executives will attend the ATTD 2026 conference in Barcelona to foster collaborations for its next-generation Continuous Glucose Monitoring (CGM) platform, CGM+. Highlighting positive clinical performance data, the company sees this as a pivotal step towards commercialization, preparing for a major clinical trial. The conference provides an opportunity for the company to engage with potential partners in research and distribution as they move forward with their innovative diabetes management solutions.
Read more →TRIB▼ -6.7%on this newsshared move
Trinity Biotech Provides Business and Trading Update
Trinity Biotech plc has provided an update on its trading activities for Q4 2025, projecting revenues between $11.5 million and $12.5 million, down from $15.9 million in Q4 2024. This decrease is attributed to disruptions in the global HIV testing market and the transition to outsourced manufacturing under its Comprehensive Transformation Plan. The company is focused on advancing commercial efforts in HIV testing and diabetes management, while also pursuing regulatory approvals for new products. These moves are part of a broader strategy aimed at long-term profitable growth.
Read more →TRIB▼ -6.7%on this newsshared move
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
Trinity Biotech has announced major advancements in its CGM+ platform, which enhances glucose measurement accuracy and aims for a pivotal clinical trial initiation in 2026. The updated device, incorporating advanced electronics and AI-native analytics, seeks to improve sustainability and reduce costs in glucose monitoring. The company is positioned to capture significant market growth in the $15 billion continuous glucose monitoring space, leveraging its cutting-edge technology. The developments are anticipated to contribute substantially to the company's growth and presence in the healthcare market.
Read more →TRIBTrinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Trinity Biotech has entered into a $25 million Standby Equity Purchase Agreement with Yorkville Advisors to enhance its commercialization and R&D efforts. The financing aims to support the company's growth, particularly in HIV testing and the development of its next-generation glucose monitoring platform, CGM+. The company anticipates continued operational progress into 2026.
Read more →TRIBTrinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
Trinity Biotech has received a notice from Nasdaq indicating it no longer meets the minimum market value of publicly held shares, which is set at $15 million. The company has until August 18, 2026, to regain compliance; failure to do so could lead to delisting from the Nasdaq. Although there is a possibility for the company to apply for transfer to the Nasdaq Capital Market, success in an appeal against delisting is not assured. This situation raises concerns regarding Trinity Biotech's operational stability.
Read more →TRIBTrinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement
Trinity Biotech received a non-compliance notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 for its American Depositary Shares. The company has a grace period of 180 days, until August 10, 2026, to achieve compliance by maintaining the required bid price for at least ten consecutive business days. While there are no immediate consequences for trading, management is evaluating options to address the issue and maintain the listing. The current bid price has been below the stipulated level for the past 30 days.
Read more →TRIB▼ -5.4%on this newsshared move
Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
Trinity Biotech has secured regulatory approval to commence upstream manufacturing of its Uni-Gold™ HIV rapid test. This approval allows the company to implement an offshore and outsourced production model, enhancing cost efficiency and scalability. The move is part of Trinity's Comprehensive Transformation Plan aimed at improving financial performance and market reach.
Read more →TRIB▲ +8.7%on this newsshared move
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
Trinity Biotech has announced that its Premier Hb9210™ HbA1c Analyser has received the prestigious IFCC Gold Classification for 2026, marking it as the only system globally to achieve this recognition. This milestone underscores the company's commitment to innovation in diabetes care. The new Buffer A Plus column system enhances usability and reduces costs while maintaining high patient care standards. Trinity Biotech's executives will showcase these advancements at the World Health Expo in February 2026.
Read more →TRIB▼ -20.3%on this news· ran to -36% by day 3
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
Trinity Biotech has entered into agreements with Perceptive Advisors to enhance its capital structure and financial flexibility. These arrangements aim to support the company's growth initiatives, particularly in diabetes management and diagnostics. The agreements also extend the maturity of the credit agreement to early 2027, allowing for continued investment in strategic priorities.
Read more →TRIB▲ +43.5%on this newsshared move
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
Trinity Biotech plc has been awarded a substantial order for 9 million units of its TrinScreen HIV tests, indicating a recovery in the global HIV testing market. The company reported a 32% increase in revenues for Q3 2025 and achieved positive Adjusted EBITDA, signaling ongoing operational improvements. Furthermore, Trinity Biotech is making progress on its Comprehensive Transformation Plan, adapting its manufacturing processes to meet rising demand. The company's strategic initiatives are expected to enhance profitability as they expand their offerings internationally.
Read more →TRIB▼ -12.1%on this news
Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
Trinity Biotech has secured regulatory clearances for its high-capacity HbA1c column system, enabling its rollout in over 10 countries, including the U.S. This advancement enhances testing efficiency and supports recurring revenue opportunities. The global HbA1c market is projected to grow significantly, positioning Trinity Biotech favorably in the diabetes management sector.
Read more →TRIBTrinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation
Trinity Biotech has secured World Health Organization approval for the offshored manufacturing of its Uni-Gold HIV test. This regulatory milestone is part of a broader transformation plan aimed at improving profitability and operational efficiency. The company plans to implement this new manufacturing model in the coming months, which is expected to enhance gross margins and cash flow.
Read more →TRIBTrinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
Trinity Biotech has announced a strategic collaboration with a bioinformatics company to enhance the EpiCapture prostate cancer test, which utilizes DNA methylation patterns for non-invasive monitoring. This collaboration aims to support the test's progression towards regulatory approval and commercialization. The EpiCapture test has shown potential in accurately predicting high-grade prostate cancers, which could improve patient outcomes and reduce invasive procedures.
Read more →TRIBTrinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
Trinity Biotech has welcomed a proposal from its largest investor, Perceptive Advisors, to convert part of its outstanding debt into equity. This strategic move is expected to strengthen the company's balance sheet and improve financial flexibility, supporting its growth objectives. Discussions are anticipated to align with stakeholder interests.
Read more →TRIB▼ -5.4%on this news· ran to -22% by day 3
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
Trinity Biotech plc has announced that it has regained compliance with Nasdaq's minimum bid price and market value requirements. This follows a period of non-compliance earlier in the year. The company has demonstrated a closing bid price of $1.00 per share or greater and a market value of publicly held shares exceeding $15 million. However, future compliance is uncertain.
Read more →TRIB▼ -10.3%on this news
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
Trinity Biotech has appointed Paul Tivnan as a Non-Executive Director to its Board. With over 25 years of experience in finance and corporate governance, Tivnan's expertise is expected to aid the company's growth in diagnostics and wearable health technologies. His appointment aligns with Trinity's strategy to strengthen corporate governance.
Read more →TRIB▲ +27%on this newsshared move
Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Trinity Biotech has received regulatory approval to commence offshore and outsourced manufacturing of its TrinScreen™ HIV rapid test. This strategic move is expected to enhance scalability, reduce fixed costs, and improve gross margins. The transition marks a significant milestone in the company's transformation strategy, aiming for long-term financial health.
Read more →TRIB▲ +89.1%on this news
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
Trinity Biotech has received regulatory approval from the New York State Department of Health to launch its FDA-cleared PreClara™ Ratio biomarker test for assessing preeclampsia risk. This test aims to provide critical insights for clinicians managing hypertensive disorders in pregnant women. The service is expected to roll out in Q3 2025, marking a significant advancement in maternal health diagnostics.
Read more →TRIB▲ +35.6%on this news· ran to +94% by day 3shared move
Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor
Trinity Biotech announced significant clinical trial results for its redesigned CGM+ sensor, which provides accurate glucose readings for 15 days without finger-stick calibration. This breakthrough aims to lower costs and enhance accessibility in diabetes management. The company is positioned to capitalize on the growing CGM market, projected to reach $28 billion by 2030.
Read more →TRIB▲ +7.4%on this news· ran to +36% by day 3shared move
Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service
Trinity Biotech has announced the launch of its FDA-cleared Preeclampsia testing service called the PreClara Ratio (sFlt-1/PlGF), aimed at improving maternal health diagnostics. This new service, set to roll out in Q3 2025, will be offered through a collaboration with Thermo Fisher Scientific and seeks to provide crucial insights for healthcare providers managing hypertensive disorders in pregnant women. Clinical studies suggest that implementing this test could lead to significant cost savings and better health outcomes for patients. The initiative marks an important milestone in Trinity Biotech's strategy to focus on enhancing care in critical clinical areas.
Read more →TRIBTrinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market
Trinity Biotech has launched CGM+, a next-generation AI-native continuous glucose monitoring system designed for the expanding AI wearables market. This innovative device combines glucose monitoring with additional health metrics like heart activity and body temperature. The company aims to position itself at the forefront of intelligent wearables, with a commercial launch expected in mid-2026, opening new revenue opportunities.
Read more →TRIB▲ +7.4%on this news
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround
Trinity Biotech has announced that it has reached a significant profitability inflection point, projecting Adjusted EBITDA-positive operations starting in Q2 2025. The company anticipates being cash flow positive from ongoing activities beginning Q3 2025. This achievement is part of its comprehensive transformation strategy aimed at enhancing financial stability and growth.
Read more →TRIB▲ +27%on this news
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
Trinity Biotech plc has secured regulatory approval from the World Health Organization for the offshored and outsourced manufacturing of its flagship TrinScreen HIV rapid test. This move is part of a broader transformation strategy aimed at improving the company's financial performance and operational efficiency. The new outsourcing model is anticipated to yield higher gross margins and free up working capital, enhancing the company's supply chain and scalability. The implementation is scheduled to commence in the third quarter of 2025.
Read more →TRIBTrinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
Trinity Biotech has announced its financial results for the fourth quarter and fiscal year 2024, highlighting a revenue increase for Q4 but also a notable net loss. The company is transitioning to offshore manufacturing to enhance profitability, with successful approvals from the WHO. While Point-of-Care revenue surged significantly, overall clinical laboratory revenues saw a decrease. The outlook remains cautiously optimistic as demand for rapid HIV tests stabilizes, although prior losses and operational restructuring present challenges.
Read more →TRIBTrinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
Trinity Biotech has received non-compliance notices from Nasdaq for failing to meet minimum bid price and market value requirements. Specifically, the company must ensure its American depositary shares maintain a closing bid price of at least $1.00 and a market value of publicly held shares exceeding $15 million within the next 180 days. Failure to comply could lead to delisting, although the company is currently still trading. Management plans to monitor their compliance status and explore options to meet the requirements.
Read more →TRIBTrinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
Trinity Biotech plc has appointed Barclays Capital as its exclusive financial advisor to support the strategic realignment of its business, with a focus on the development of continuous glucose monitoring (CGM) technology. This decision is part of the company's comprehensive transformation plan aimed at improving profitability and optimizing its business portfolio. The company's management is optimistic about the market potential for their innovative CGM solutions, supported by favorable pre-pivotal clinical trial data. The strategic shift reflects Trinity Biotech's commitment to capitalize on growth opportunities within the diabetes management space.
Read more →TRIBTrinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology
Trinity Biotech plc has secured an additional $4 million in debt financing to support its transformation plan and the development of its continuous glucose monitoring (CGM) technology. The funding aims to enhance the company's growth prospects and operational efficiencies. Positive results from a recent trial have bolstered confidence in their CGM technology. However, the company also faces various risks, including profitability challenges and dependency on market acceptance.
Read more →TRIB▼ -7.2%on this news
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
Trinity Biotech announced remarkable improvements in first-day accuracy for its next-generation continuous glucose monitoring (CGM) system in its latest pre-pivotal trial, showing significant advancements over its earlier Waveform product. The study revealed a 35% improvement in Mean Absolute Relative Difference (MARD) and over 50% in Mean Absolute Difference (MAD), addressing a critical pain point in CGM accuracy for diabetic patients. The redesigned sensor aims to make CGM more affordable and accessible, aligning with industry standards, and positions Trinity well for upcoming regulatory submissions in Europe and the USA.
Read more →TRIB▲ +78.9%on this news
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech announced promising results from its pre-pivotal clinical trial for a next-generation continuous glucose monitoring (CGM) system, aimed primarily at individuals with Type 1 diabetes. The trial reported significant enhancements in sensor accuracy and reliability, positioning Trinity's CGM as a disruptive, affordable solution in the market. The company plans to file for regulatory approvals in the EU and the U.S. in 2025 and 2026, respectively, aiming to expand access to diabetes management technologies for a broader audience. With the combination of sustainable design and improved performance, the new system has the potential to revolutionize the CGM landscape.
Read more →TRIB▼ -7.7%on this news
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
Trinity Biotech plc (TRIB) has entered into amended agreements with Perceptive Advisors to improve its liquidity as part of its Comprehensive Transformation Plan. These amendments include a $5 million deferred payment extension and approximately $5.5 million in additional liquidity. The funding is expected to support key initiatives, including the development of continuous glucose monitoring technology. Additionally, the company's recent WHO approval for the transfer of HIV manufacturing to a lower-cost partner is seen as a pivotal step in their strategic objectives.
Read more →TRIBTrinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV
Trinity Biotech plc has announced that it has received early approval from the World Health Organization to initiate the offshore manufacturing of its rapid HIV tests, TrinScreen HIV and Uni-Gold HIV. This approval allows the company to proceed with a key aspect of its Comprehensive Transformation Plan aimed at enhancing efficiency and cost-effectiveness. The manufacturing is expected to commence in Q1 of 2025, which could lead to improved margins and overall growth for the company. CEO John Gillard emphasized the significance of this regulatory approval in bolstering shareholder value and acknowledged the efforts of the team in achieving this expedited approval.
Read more →TRIB▼ -7.4%on this news
Trinity Biotech Announces Q3 2024 Financial Results
Trinity Biotech reported Q3 2024 revenues of $15.2 million, reflecting a 3% increase from the previous year, driven mainly by a 60% growth in Point-of-Care product sales. The company continues to focus on a Comprehensive Transformation Plan, expecting to achieve $20 million in annualized run-rate EBITDASO by Q2 2025. Despite positive sales growth, there were operational losses and a decline in clinical laboratory revenue. Additionally, challenges with profit margins in new products were highlighted.
Read more →TRIBTrinity Biotech to Announce Q3 2024 Financial Results
Trinity Biotech plc, a biotechnology company specializing in diabetes management solutions and diagnostics, has announced that it will report its financial results for Q3 2024 on November 15, 2024. A conference call is scheduled for the same day at 10:00 AM ET to discuss these results. The company continues to develop diagnostic systems and has recently ventured into the wearable biosensor market through an acquisition. Trinity Biotech markets its products in multiple countries, enhancing its global reach.
Read more →TRIB▲ +5.5%on this news· ran to +20% by day 1
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
Trinity Biotech has acquired EpiCapture Limited, entering the oncology diagnostics market with a non-invasive test aimed at monitoring aggressive prostate cancer. The EpiCapture test utilizes epigenetic analysis to detect DNA methylation patterns associated with high-grade cancer, potentially reducing the need for invasive biopsies. This strategic move aligns with Trinity Biotech's commitment to advancing diagnostic solutions and improving patient quality of life. The acquisition is valued at approximately $3 million with additional milestone payments contingent on future success.
Read more →TRIB▲ +5.5%on this news· ran to +20% by day 1
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
Trinity Biotech has announced a strategic investment of approximately $2.5 million into Novus Diagnostics to foster the development of its rapid sepsis testing platform. The investment will help in accelerating the commercialization of a 15-minute bloodstream infection test aimed at enhancing quick diagnosis and treatment, a significant improvement over current methods. This innovative diagnostic solution is expected to aid in reducing mortality rates associated with sepsis and lower healthcare costs in the U.S.
Read more →TRIB▲ +13.3%on this news· ran to +51% by day 3
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
Trinity Biotech plc announced positive results from its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The trial demonstrated improvements in the device's analytical performance following significant upgrades made since its acquisition from Waveform Technologies. The company plans to conduct a second European pre-pivotal trial later this year, which will inform further optimizations and pave the way for a pivotal trial in 2025. With projected growth in the CGM market, Trinity Biotech is positioned to offer an affordable and innovative solution for diabetes management.
Read more →TRIBTrinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
Trinity Biotech has acquired Metabolomics Diagnostics for approximately $1.3 million, enhancing its capabilities in maternal health diagnostics. The acquisition focuses on the PrePsia test, which can predict the risk of preeclampsia as early as the 12th week of pregnancy, allowing for early medical interventions. The test is set to launch in the U.S. market in 2025, leveraging Trinity's New York-based Immco laboratory. This strategic move aligns with Trinity's growth initiatives in biomarker analyses combined with advanced machine learning technology.
Read more →TRIB▼ -6.2%on this news· ran to -22% by day 3
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
Trinity Biotech plc has announced plans to initiate a market study for its next generation Continuous Glucose Monitoring (CGM) technology in India, as part of a collaboration with Bayer. This study will gather feedback from diabetes patients and healthcare professionals to refine the CGM device design in preparation for its launch. India, with over 100 million diabetics, faces a public health challenge, and Trinity aims to improve access to CGM technology at a lower cost. The study is expected to contribute to understanding and optimizing CGM utilization in the Indian healthcare market.
Read more →TRIBTrinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
Trinity Biotech has provided an update on the continued development of its glucose biosensor technology, which recently received a European patent for an innovative process aimed at enhancing performance. This patented method has shown effectiveness in reducing run-in time, thereby providing more reliable glucose measurements quickly. The company is focused on refining its CGM technology to improve accuracy and user experience. Upcoming pre-pivotal trials will further evaluate the enhancements before introducing the optimized product to global markets.
Read more →TRIB▼ -9.5%on this news
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
Trinity Biotech plc has appointed Adrian Donohue as Chief Commercial Officer, tapping into his 25 years of experience in the healthcare sector. This strategic move aligns with the company's ongoing transformation agenda aimed at enhancing performance and profitability, particularly through their innovative continuous glucose monitor (CGM) products. Mr. Donohue's role will also involve overseeing the rollout of their rapid HIV testing product, TrinScreen HIV. The company anticipates that his leadership will contribute significantly towards achieving its growth objectives in the competitive diagnostics market.
Read more →TRIBTrinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
Trinity Biotech plc has announced a substantial increase in orders for its TrinScreen HIV product, leading to a revised sales revenue projection of approximately $10 million for 2024, up from $8 million. The company's CEO, John Gillard, highlighted the successful scaling of production capacity to meet rising demand. In addition to TrinScreen, Trinity Biotech is also increasing production for FlexTrans™, its viral transport medium, in response to global health concerns regarding Mpox. This reflects the company’s commitment to improving diagnostic solutions for infectious diseases.
Read more →TRIBTrinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
Trinity Biotech has appointed David Ouston as the new Biosensor Marketing Director, bringing significant experience from his previous roles in glucose monitoring. CEO John Gillard expressed optimism about the company's focus on innovative continuous glucose monitoring (CGM) technology, suggesting it will be a critical growth driver. Ouston himself noted his enthusiasm for supporting Trinity Biotech's vision for expanding access to biosensor technology and enhancing public health.
Read more →TRIBTrinity Biotech Announces Q2 2024 Financial Results
Trinity Biotech announced robust financial results for Q2 2024, with total revenues of $15.8 million, reflecting a 14% increase year-over-year. Significant growth was observed in the Point-of-Care products, which saw a 119% rise from the previous year. The company reiterated its guidance for achieving approximately $20 million in annualized run-rate EBITDASO by the second quarter of 2025. However, it faces challenges related to gross margin pressure from its TrinScreen HIV product and temporary declines in clinical laboratory revenues. The company is also executing a Comprehensive Transformation Plan aimed at improving profitability and efficiency across its operations.
Read more →TRIBTrinity Biotech to Announce Q2 2024 Financial Results
Trinity Biotech plc is set to announce its financial results for the second quarter of 2024 on August 14, 2024. The company, which specializes in diabetes management and human diagnostics, has recently entered the wearable biosensor market and plans to develop various biosensor devices. They currently operate in multiple regions including the United States, Germany, France, and the U.K., and sell through a wide network of international distributors.
Read more →TRIB▼ -11%on this news
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
Trinity Biotech plc has received an extension from the Nasdaq Hearings Panel until October 31, 2024, to demonstrate compliance with the minimum market value requirement for continued listing. This development follows a deficiency letter notifying the company of its failure to maintain the necessary market value of publicly held shares. The extension grants Trinity Biotech critical time to implement its compliance strategy amidst ongoing efforts to enhance its diagnostic and diabetes management solutions.
Read more →TRIBTrinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
Trinity Biotech announced that preliminary revenues for the second quarter of 2024 are expected to range between $15.5-$16.0 million, reflecting strong year-over-year growth. The company reiterated its financial guidance for achieving approximately $20 million in annualized EBITDASO by Q2 2025. Additionally, Trinity Biotech has entered a distribution agreement with MedScience for its clinical chemistry and infectious disease products in the UK, effective August 1, 2024. This partnership aims to expand Trinity's market presence in the UK and further support revenue growth initiatives.
Read more →TRIB▲ +13.6%on this news· ran to +54% by day 3
Trinity Biotech Announces Appointment of A New CFO
Trinity Biotech has announced the appointment of Louise Tallon as Chief Financial Officer, effective August 2024. Tallon brings nearly two decades of experience in finance within the life sciences industry. The company also reiterated its financial guidance, aiming for approximately $20 million of annualized EBITDASO by Q2 2025. Des Fitzgerald will remain as interim CFO until late July 2024, and Simon Dunne will exit the company in August 2024, with Tallon assuming his role.
Read more →TRIBTrinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
Trinity Biotech plc has announced the commencement of its initial European pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) technology. Regulatory approval has been granted, allowing the company to assess enhancements to the CGM device, with the trial expected to conclude by the end of July. The results will inform a larger pivotal trial anticipated for 2025, which is essential for product registration and market launch. The CEO expressed confidence in the CGM solution as a significant growth driver for the company.
Read more →TRIB▲ +8.6%on this news· ran to +65% by day 3
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
Trinity Biotech plc, a biotechnology company focusing on diabetes management and diagnostics, will attend the 84th Scientific Sessions of the American Diabetes Association from June 21-24, 2024. The company's senior management intends to engage with key stakeholders and potential partners to promote its recently acquired continuous glucose monitoring biosensor technology. This appearance at a significant industry event highlights Trinity's commitment to advancing innovative solutions in diabetes care.
Read more →TRIBTrinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
Trinity Biotech has launched a microsite dedicated to their continuous glucose monitoring (CGM) technology, aiming to enhance visibility and understanding among stakeholders. The site will provide insights into their innovative CGM biosensor technology and AI-driven health analytics platform. CEO John Gillard stated that the new technology focuses on usability, affordability, and sustainability, addressing the significant unmet needs of diabetes patients globally. The company is optimistic about potential market acceptance and future growth.
Read more →TRIBTrinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
Trinity Biotech announced its Q1 2024 financial results, showing strong sequential growth, particularly a 39% increase in Point-of-Care revenues driven by the successful rollout of their TrinScreen HIV product. The company reported a 40% reduction in net loss as they focused on operational efficiencies, with expectations of further improvements in gross margin through 2024. Despite a slight decrease in total revenues compared to the previous year, management reiterated its guidance for annualized revenue growth, predicting significant progress by Q2 2025.
Read more →TRIBTrinity Biotech plc to Announce Q1 2024 Financial Results
Trinity Biotech plc will announce its financial results for Q1 2024 on May 23, 2024, at 8:30 AM ET. The firm, focused on diabetes management and human diagnostics, is expanding its capabilities with wearable biosensors. Investors and stakeholders can participate in the accompanying conference call to discuss the upcoming results and strategies. The company has made recent advancements by acquiring Waveform Technologies Inc.'s biosensor assets.
Read more →TRIBTrinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
Trinity Biotech has announced a strategic collaboration with PulseAI to enhance its recently acquired continuous glucose monitor (CGM) biosensor technology. This partnership will leverage multi-parameter CGM datasets from Trinity Biotech’s existing database to design an AI-driven health analytics platform, aimed at improving user experience and providing detailed metabolic insights. The collaboration positions Trinity Biotech to launch an affordable, needle-free diabetes management solution across global markets. Both companies expressed optimism over the potential for future innovations in glucose monitoring and health analytics.
Read more →TRIB▼ -7.1%on this newsshared move
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
Trinity Biotech plc has announced increased orders for its TrinScreen HIV product, totaling approximately $6 million, and has successfully scaled production to meet demand. As a result, the company has raised its 2024 sales revenue guidance for TrinScreen HIV to over $8 million. Despite this positive momentum, the company acknowledges potential risks including inventory imbalances and dependence on supplier reliability.
Read more →TRIBTrinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
Trinity Biotech has appointed Avinash Kale as the Continuous Glucose Monitor Programme Director, marking a crucial advancement for the company's recently acquired CGM technology. The appointment aims to enhance innovation and development in delivering an advanced CGM solution globally. Kale brings extensive leadership experience from prominent firms and is expected to contribute significantly to Trinity Biotech's mission of making wearable biosensors accessible to diabetes patients. The company underscores its goal of expanding the technology's reach and increasing shareholder value through strategic investments and talent acquisition.
Read more →TRIBTrinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
Trinity Biotech plc reported its financial results for Q4 2023 and fiscal year 2023, highlighting a comprehensive transformation plan aimed at enhancing operational efficiency and profitability. The plan includes consolidating manufacturing operations and reducing costs through supplier negotiations. Additionally, the company is advancing its wearable biosensor technology portfolio, with an emphasis on next-generation glucose monitors. Despite a 14.6% revenue decline in Q4 2023, Trinity Biotech recognizes key opportunities in the diabetes management sector and HIV testing markets.
Read more →TRIBTrinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
Trinity Biotech plc (TRIB) will announce its fourth quarter and fiscal year 2023 financial results on April 4, 2024, at 8:00 AM ET. The company's financial performance will be discussed during a conference call, which will be accessible via dial-in and webcast. Trinity Biotech specializes in diagnostic solutions for both point-of-care and clinical laboratory markets, with a wide product range aimed at detecting infectious diseases and assessing various health parameters. The company operates globally with a strong presence in Europe and the U.S.
Read more →TRIBTrinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Trinity Biotech Plc has received formal notification from Nasdaq that it has regained compliance with the minimum closing bid price requirement. The company’s American Depositary Shares maintained a bid price of $1.00 or more for ten consecutive trading days. As a result, the bid price deficiency issue is now considered closed by Nasdaq. This development may bolster investor confidence in Trinity Biotech's operations and market standing.
Read more →TRIBTrinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
Trinity Biotech Plc has announced the effective date for its change in American depositary share (ADS) ratio, which is intended to assist in compliance with Nasdaq's minimum bid price requirement. The new ratio of one ADS representing twenty Class A ordinary shares will be effective as of February 23, 2024. This adjustment is akin to a one-for-five reverse ADS split, reflecting the company's efforts to stabilize its market position. While the company aims for compliance, concerns around profitability and market acceptance persist.
Read more →TRIBTrinity Biotech Plc Announces Plan to Implement ADS Ratio Change
Trinity Biotech Plc has announced a change in its American depositary shares (ADS) ratio from one ADS representing four Class A ordinary shares to one ADS representing twenty. This adjustment, akin to a one-for-five reverse ADS split, aims to help the company meet Nasdaq's minimum bid price and attract a larger investor base. The effective date for this change is set for February 21, 2024, with ADS holders required to exchange their old shares for new ones. While the company anticipates a proportional increase in ADS prices, no assurances can be given regarding the outcome.
Read more →TRIBTrinity Biotech to Present at Emerging Growth Conference
Trinity Biotech plc will present virtually at the Emerging Growth Conference on March 7, 2024. The presentation invites both individual and institutional investors, alongside advisors and analysts, to engage in a real-time interactive session. Trinity Biotech develops diagnostic systems aimed at both point-of-care and clinical laboratory markets, with a global presence across multiple countries.
Read more →TRIB▼ -8.6%on this newsshared move
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
Trinity Biotech has announced that its New York-based Immco Diagnostics has applied for a Proprietary Laboratory Analyses (PLA) code for the Early Sjögren's Syndrome Test Panel. This initiative aims to optimize market access and improve profitability while facilitating better patient access to the diagnostic tool. Sjögren's Syndrome affects up to 3 million individuals in the US, highlighting the need for effective diagnostic solutions. Approval of the PLA code is anticipated in Q3 2024, which could enhance the commercial viability of the test panel.
Read more →TRIB▲ +35.7%on this news
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
Trinity Biotech plc (Nasdaq: TRIB) released its Q3 2023 financial results and announced several key strategic decisions, including the acquisition of Waveform Technologies' biosensor assets. The new management team aims to enhance profitability through optimization of existing products, such as their rapid HIV test manufacturing and Diabetes HbA1c testing systems. The company is also partnering with Bayer to launch a CGM device in China and India. Additionally, an amended credit agreement has provided additional funds to support these initiatives. Revenue for Q4 2023 is projected to be between $13 million and $14 million, maintaining gross margin stability.
Read more →TRIB▲ +35.7%on this news
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
Trinity Biotech plc has announced a non-binding Letter of Intent with Bayer to explore a joint partnership for launching a Continuous Glucose Monitoring (CGM) biosensor device in China and India. This move follows Trinity's recent acquisition of CGM assets from Waveform Technologies. The partnership aims to leverage Bayer's strong presence in these markets to improve the affordability and accessibility of diabetes care amid rising diabetes prevalence. Both companies plan to negotiate a definitive agreement in the coming months to solidify this collaboration.
Read more →TRIB▲ +35.7%on this news
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
Trinity Biotech has announced its acquisition of the CGM assets from Waveform Technologies for $12.5 million in cash and 9 million ADSs. This move is part of Trinity's strategy to strengthen its position in the wearable biosensor market, with initial focus on transforming the acquired CGM technology to provide comprehensive health insights. The company has also secured additional funding from Perceptive Advisors to support this initiative. The acquisition includes contingent considerations based on future performance metrics.
Read more →TRIBTrinity Biotech plc to Host Investor Call
Trinity Biotech plc will host an investor call on January 31, 2024, at 8:30 AM ET to provide an update on its business operations. The company specializes in diagnostic solutions for point-of-care and clinical laboratory markets. This call aims to engage with investors and share insights into current performance and future prospects. As a leading manufacturer in the medical diagnostics field, Trinity Biotech operates in multiple countries across the globe.
Read more →TRIBTrinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
Trinity Biotech has initiated shipments of its TrinScreen HIV, a new rapid HIV screening test, to Kenya, which represents a significant milestone for the company. The Kenyan government has committed to procure up to 10 million tests in 2024, funded by global sponsors such as USAID. This movement is part of the country's efforts to implement a revised WHO HIV testing algorithm. Trinity Biotech anticipates additional orders as it seeks to expand its market presence in Africa.
Read more →TRIBTrinity Biotech Announces Management Changes
Trinity Biotech has announced the promotion of John Gillard to President and Chief Executive Officer, effective immediately. Des Fitzgerald has been appointed as Interim Chief Financial Officer, replacing Gillard. This leadership change comes as former CEO Aris Kekedjian resigns from the position. Gillard aims to enhance the company's existing capabilities and pursue new technological directions while focusing on growth and shareholder value.
Read more →TRIB▲ +7.9%on this news
Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
Trinity Biotech welcomed a recent ruling from the High Court of Kenya that dismissed a lawsuit attempting to block the procurement of its TrinScreen HIV test kits by the Kenyan Ministry of Health. This decision eliminates legal barriers and enables Trinity Biotech to supply its HIV test kits in Kenya, where the annual screening program is sizable, involving approximately 10 million tests. The company anticipates receiving orders soon, marking a positive milestone for both its operations and public health efforts in the region.
Read more →TRIBTrinity Biotech Announces Q2 2023 Financial Results
Trinity Biotech announced its Q2 2023 financial results, revealing total revenue of $13.9 million. Notably, Diabetes consumables saw a robust increase, particularly a 70% rise in the Asia region driven by demand recovery in China. However, overall revenue dropped 3% compared to the previous quarter, influenced by reduced sales in Infectious Disease products. The company has also received FDA clearance for its Premier Resolution System and is focused on operational transformations to enhance cash flow and set the stage for future growth.
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
Trinity Biotech plc is set to announce its financial results for the second quarter of fiscal year 2023 on October 3, 2023. A conference call will follow to discuss these results, inviting stakeholder participation via a toll-free number and an international dial-in. The company emphasizes the forward-looking nature of the statements made, acknowledging risks linked to research, competition, and regulatory compliance. Interested parties can access a webcast of the call, along with options for replay available for a limited time.
Read more →TRIB▲ +21.1%on this news
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
Trinity Biotech plc has received a non-compliance notice from Nasdaq, indicating that the company's American depositary shares (ADSs) have not met the minimum bid price of $1.00 for 30 consecutive business days. This notice does not immediately affect the trading of the ADSs, which are listed under the symbol 'TRIB'. The company has until March 6, 2024, to regain compliance by maintaining the required bid price. If compliance is not achieved, Trinity may qualify for an additional grace period if certain criteria are met.
Read more →TRIB▼ -16.8%on this news
Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
Trinity Biotech has announced that its Premier Resolution System has received 510(k) clearance from the U.S. FDA. This system enables accurate quantification and detection of hemoglobin variants, which are essential for diagnosing various medical conditions such as thalassemias and Sickle Cell Disease. The technology is intended to enhance the company's position in the diagnostic market and facilitate entry into additional international markets. Furthermore, the clearance signifies a key milestone in the company's strategic transformation and product expansion plans.
Read more →TRIB▼ -13.1%on this news
Trinity Biotech Announces Q1 2023 Financial Results
Trinity Biotech plc has announced its Q1 2023 financial results, reporting total revenues of $17.2 million, a 2.0% increase from the previous year when adjusted for specific divestments. Notably, the company experienced strong growth in Autoimmune and diabetes monitoring products, contributing to a significant 80% revenue increase in US Autoimmune products compared to the same quarter last year. Additionally, Trinity Biotech is progressing towards the FDA clearance of its new Premier Resolution Haemoglobin Variants instrument and is set to roll out its next-generation diabetes instrument in 2024. The company is also focusing on expanding its market presence in China and Brazil while capitalizing on its partnership with the Kenyan Ministry of Health for HIV screenings.
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
Trinity Biotech plc (Nasdaq: TRIB) is scheduled to announce its financial results for the first quarter of fiscal year 2023 on July 6, 2023. A conference call is planned for the same day at 11:00 am ET to discuss these results, which interested parties can join via phone or a webcast. The company emphasizes that its announcements may include forward-looking statements with associated risks, such as competitive pressures and regulatory challenges, as well as uncertainties from the ongoing COVID-19 pandemic.
Read more →TRIBTrinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth
Trinity Biotech plc announced the successful closing of the $30 million sale of its Fitzgerald Industries life sciences supply business to Biosynth. Approximately $11 million of the proceeds were utilized to repay senior secured debt to Perceptive Advisors, significantly lowering the company's minimum revenue covenants under its loan. The sale aims to strengthen Trinity Biotech's financial position in the diagnostic solutions market.
Read more →TRIB▲ +25.3%on this newsshared move
Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth
Trinity Biotech has announced the sale of its Fitzgerald Industries life sciences supply business to Biosynth for around $30 million. This transaction aligns with Trinity's strategic shift towards becoming a leader in diabetes care and decentralized diagnostics. The sale is expected to significantly reduce the company's net debt and improve its balance sheet. The transaction is set to close in April 2023, further enabling Trinity Biotech to focus on its core growth areas.
Read more →TRIBTrinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
Trinity Biotech plc announced its financial results for Q4 and the fiscal year 2022, revealing total revenues of $74.8 million, slightly down from 2021. The company showcased strong growth in its diabetes product line, with a 27% increase in overall revenue and significant expansion plans, including new product launches. However, challenges remain, particularly in the HIV sector, which experienced a notable decline in revenue. Looking ahead, the company aims to optimize its portfolio and explore strategic acquisitions to enhance shareholder value.
Read more →TRIBTrinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm
Trinity Biotech announced that its TrinScreen HIV has been included as the screening test in the Kenyan HIV testing algorithm, a significant endorsement from the Kenyan Ministry of Health. This algorithm is crucial, given the large scale of HIV screening in Kenya, with millions of tests conducted annually. The adoption reflects Trinity Biotech's longstanding commitment to quality HIV testing in Africa and positions the company for potential growth in other markets across the continent as well. The company is ramping up production capabilities in preparation for increased demand.
Read more →TRIB▼ -5.2%on this news
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
Trinity Biotech plc will announce its financial results for the fourth quarter and fiscal year 2022 on March 23, 2023. The company has organized a conference call at 10:00 AM ET on the same day to discuss these results. Interested parties can access the call via various toll numbers and a simultaneous webcast. The announcement highlights the company's ongoing operations in the diagnostic market and its commitment to engaging with investors.
Read more →TRIB▲ +11.7%on this news
Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions
Trinity Biotech plc announced an increased loan facility to enhance its potential acquisition capabilities and support ongoing operations. The amended term loan includes an immediate $5 million increase and a total funding capacity of $20 million. The company aims to leverage this financing to pursue opportunities in diabetes care and decentralized diagnostics, as indicated by statements from its CEO and CFO. This strategic move emphasizes the company's focus on growth and innovation in the diagnostic market.
Read more →TRIBTrinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry
Trinity Biotech has announced a strategic partnership with imaware to provide integrated diagnostic testing solutions to the digital health industry. The partnership will involve a $1.5M investment by Trinity Biotech and aims to process over 650,000 test kits annually within three years. This collaboration focuses on developing private and white-label solutions tailored for digital health channel partners, utilizing Trinity Biotech's advanced laboratory facilities and product development capabilities. The agreement is set to further enhance imaware's ability to deliver at-home and remote testing solutions for healthcare providers and patients.
Read more →TRIBTrinity Biotech Announces Q3 2022 Financial Results
DUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended September 30, 2022
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results
DUBLIN, Ireland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursd
Read more →TRIBTrinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference
DUBLIN, Ireland, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference
Read more →TRIBTrinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance
DUBLIN, Ireland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2022 and
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results
DUBLIN, Ireland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2022 on Thurs
Read more →TRIBTrinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors
DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces the appointment of Mr. Tom Lindsay to its Board of Directors a
Read more →TRIB▲ +12%on this news
Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO
DUBLIN, Ireland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the appointment of Mr. Aris Kekedjian as CEO with effect from
Read more →TRIBTrinity Biotech Announces Results of AGM
DUBLIN, Ireland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Annual General Meeting (AGM). On September
Read more →TRIB▼ -6.5%on this news
Trinity Biotech Announces Quarter 1 2022 Financial Results
DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022. T
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
DUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursd
Read more →TRIBTrinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
DUBLIN, Ireland, May 20, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test throughout the Eu
Read more →TRIBTrinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea
DUBLIN, Ireland, May 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced strategic investment
Read more →TRIB▲ +16.3%on this news
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal ye
Read more →TRIB▲ +16.3%on this news
Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea
DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading global diagnostic company (“Trinity Biotech” or the “Company”), today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and K
Read more →TRIBTrinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO). Trinity Biotech’s Uni-Gold™ HIV product has been the main confirmatory test p
Read more →TRIBTrinity Biotech Announces The Successful Closing of its Debt Refinancing
DUBLIN, Ireland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced refinancing. As pre
Read more →TRIBTrinity Biotech Announces That Its Shareholders Have Approved All of the Four Resolutions That Were the Subject of the EGM Held on January 25, 2022
DUBLIN, Ireland, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Extraordinary General Meeting (EGM). As pre
Read more →TRIB▼ -6.7%on this news
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company’s Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes
DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the e
Read more →TRIB▲ +10.3%on this news
Trinity Biotech Announces Results for Q2, 2021
DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021. Total revenues
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2021 Financial Results
DUBLIN, Ireland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2021 on Thurs
Read more →TRIB▲ +6.8%on this news
Trinity Biotech Provides A Business Development Update For Q2 2021
DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021. HIV Testing (TrinScreen™ HIV) Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African
Read more →TRIBTrinity Biotech Announces Results for Q1, 2021
DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Total revenues f
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2021 Financial Results
DUBLIN, Ireland, May 19, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2021 on Tuesday
Read more →TRIBTrinity Biotech Announces the Submission of TrinScreen™ HIV to the World Health Organisation for Approval
DUBLIN, Ireland, March 30, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has submitted its new HIV screening product, TrinScreen™ HIV, to the World Health Organisation (WHO) for approval. This product, once approved, will allow the Company to build on its strong pr
Read more →TRIBTrinity Biotech Announces Quarter 4 and Fiscal Year 2020 Financial Results
DUBLIN, Ireland, March 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2020 and fiscal ye
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2020 Financial Results
DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2020 on
Read more →TRIBTrinity Biotech Announces CE Mark of its Covid-19 IgG ELISA Antibody Test
DUBLIN, Ireland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia™ SARS-CoV-2 IgG ELISA. Trinity Biotech has launched the test in countries throughout the Euro
Read more →TRIBTrinity Biotech Announces Results for Q3, 2020
DUBLIN, Ireland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2020. Total reven
Read more →TRIBTrinity Biotech plc to Announce Third Quarter 2020 Financial Results
DUBLIN, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter 2020 on Tuesday, November 17, 2020.
Read more →TRIBTrinity Biotech Announces Results for Q2, 2020
DUBLIN, Ireland, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2020. Total revenues f
Read more →TRIBTrinity Biotech announces EUA submission for Covid-19 ELISA Antibody test
DUBLIN, Ireland, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets announced that it has filed its submission for an Emergency Use Authorization (
Read more →TRIBTrinity Biotech plc to Announce Second Quarter 2020 Financial Results
DUBLIN, Ireland, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter 2020 on Tuesday, August 2
Read more →TRIBTrinity Biotech subsidiary, Primus Corporation Receives FDA Warning Letter
DUBLIN, Ireland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that its subsidiary Primus Corporation has received a warning letter
Read more →TRIBTrinity Biotech Announces Results for Q1, 2020
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2020. Total revenues f
Read more →TRIBTrinity Biotech plc to Announce First Quarter 2020 Financial Results
DUBLIN, Ireland, May 14, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter 2020 on Wednesday, May 27,
Read more →TRIBTrinity Biotech announces Quarter 4 and Fiscal Year 2019 Financial Results
DUBLIN, Ireland, March 31, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2019 and fiscal ye
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2019 Financial Results
DUBLIN, Ireland, March 24, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2019 on
Read more →TRIBTrinity Biotech Announces Results for Q3, 2019
DUBLIN, Ireland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2019. Total reven
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2019 Financial Results
DUBLIN, Ireland, Oct. 15, 2019 (GLOBE NEWSWIRE) -- October 15, 2019 – Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal
Read more →TRIBTrinity Biotech Announces Results for Q2, 2019
DUBLIN, Ireland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2019. Total revenues f
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2019 Financial Results
DUBLIN, Ireland, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2019 on Tuesd
Read more →TRIBTrinity Biotech Announces Results for Q1, 2019
DUBLIN, Ireland, May 07, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2019. Total revenues f
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2019 Financial Results
DUBLIN, Ireland, May 01, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2019 on Tuesday
Read more →TRIBTrinity Biotech announces Quarter 4 and Fiscal Year 2018 Financial Results
DUBLIN, Ireland, March 07, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2018 and fiscal ye
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2018 Financial Results
DUBLIN, Ireland, March 04, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2018 on
Read more →TRIBTrinity Biotech Announces Results for Q3, 2018
DUBLIN, Ireland, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2018. Total reven
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2018 Financial Results
Conference Call Scheduled for October 23, 2018 DUBLIN, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the t
Read more →TRIBTrinity Biotech Announces Results for Q2, 2018
DUBLIN, Ireland, July 19, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2018. Total revenues fo
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2018 Financial Results
DUBLIN, Ireland, July 12, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2018 on Thursd
Read more →TRIBTrinity Biotech announces Results for Q1, 2018
DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2018. Total revenues fo
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2018 Financial Results
DUBLIN, April 20, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2018 on Tuesday, May 1,
Read more →TRIBTrinity Biotech announces Quarter 4 and Fiscal Year 2017 Financial Results
DUBLIN, Ireland , March 07, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2017 and fiscal ye
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2017 Financial Results
DUBLIN, Ireland, March 05, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2017 on
Read more →TRIBTrinity Biotech Announces Results for Q3, 2017
DUBLIN, Ireland, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2017. Total revenu
Read more →TRIBTrinity Biotech plc to Announce 2017 Third Quarter Financial Results
DUBLIN, Ireland, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report 2017 third quarter financial results on Thursday, October 26, 2017.
Read more →TRIBTrinity Biotech Announces Results for Q2, 2017
DUBLIN, Ireland, July 20, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2017. Total revenues fo
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2017 Financial Results
DUBLIN, July 03, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2017 on Thursday, July
Read more →TRIBTrinity Biotech Announces Results for Q1, 2017
DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017. Total revenues
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2017 Financial Results
DUBLIN, Ireland, April 18, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2017 on Thursd
Read more →TRIBTrinity Biotech announces Quarter 4 and Fiscal Year 2016 Financial Results
DUBLIN, Ireland, March 14, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2016 and fiscal yea
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2016 Financial Results
DUBLIN, Ireland, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2016 on Tu
Read more →TRIBPress Release dated
Press Release dated October 4, 2016 Contact: Trinity Biotech plc Lytham Partners LLC Kevin Tansley Joe Diaz, Joe Dorame & Robert Blum (353)-1-2769800 602-889-9700 E-mail: kevin.tansley@trinitybiotech.com Trinity Biotech Announces withdrawal of Troponin FDA 510(k) Submission
Read more →TRIBTrinity Biotech announces Quarter 3 Financial Results
DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2016. Total revenu
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2016 Financial Results
DUBLIN, Ireland, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2016 on Tuesday
Read more →TRIBTrinity Biotech Announces withdrawal of Troponin FDA 510(k) Submission
DUBLIN, Ireland, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced today that it is withdrawing its 510(k) premarket notification submis
Read more →TRIBTrinity Biotech Announces Quarter 2 Financial Results
DUBLIN, Ireland, July 21, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2016. Total revenues fo
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2016 Financial Results
DUBLIN, Ireland, July 14, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2016 on Thursd
Read more →TRIBTrinity Biotech Announces Results for Q1, 2016
DUBLIN, April 19, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2016. Total revenues for Q1, 2
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2016 Financial Results
DUBLIN, April 15, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2016 on Tuesday, April
Read more →TRIBTrinity Biotech Announces Results for Q4 and Fiscal Year 2015
DUBLIN, March 03, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for fiscal year 2015 and the quarter ended December 31, 2015. T
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2015 Financial Results
DUBLIN , Feb. 26, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2015 on Thursday,
Read more →TRIBTrinity Biotech Announces FDA Submission of High Sensitivity Troponin I Product
DUBLIN, Ireland, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB) is pleased to announce today that it has submitted to the U.S. Food and Drug Administration (FDA), for 510(k) clearance, its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI)
Read more →TRIBTrinity Biotech Announces Quarter 3 Financial Results
DUBLIN, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2015. Total revenues for Q3
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2015 Financial Results
DUBLIN, Ireland, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2015 on Thursda
Read more →TRIBTrinity Biotech Announces Quarter 2 Financial Results Enrolment for the Meritas Troponin ACS Study Now Completed
DUBLIN, July 28, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2015. Total revenues for Q2, 201
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2015 Financial Results
DUBLIN, July 17, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2015 on Tuesday, July 2
Read more →TRIBTrinity Biotech Announces Quarter 1 Results -- EPS 17.4 Cents Dividend of 22 Cents
DUBLIN, Ireland, April 30, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2015. Total revenues
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2015 Financial Results
DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2015 on Thursd
Read more →TRIBTrinity Biotech plc Closes Offering of $115 Million of 4.00% Exchangeable Senior Notes Due 2045, Including Exercise in Full of Option to Purchase Additional Notes
DUBLIN, Ireland, April 9, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced today that Trinity Biotech Investment Limited, its wholly-owned subsi
Read more →TRIBTrinity Biotech Announces Filing of 2014 Annual Report
DUBLIN, March 25, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has filed its Form 20-F containing audited consolidated financi
Read more →TRIBTrinity Biotech Announces Results for Q4 and Fiscal Year 2014
DUBLIN, Ireland, March 3, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for fiscal year 2014 and the quarter ended December 31,
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2014 Financial Results
DUBLIN, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2014 on Tuesday, Ma
Read more →TRIBTrinity Biotech Announces Recommencement of US Clinical Trials on Its Point-of-Care, High Sensitivity Troponin I Product
DUBLIN, Ireland, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that late last week it shipped Meritas Troponin I product to t
Read more →TRIBTrinity Biotech Announces CLIA Waiver of Rapid Syphilis Test
DUBLIN, Ireland, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that a CLIA waiver has been received for Syphilis Health Check
Read more →TRIBTrinity Biotech Announces Quarter 3 Financial Results and Temporary Suspension of Meritas Troponin Trials
DUBLIN, Ireland, Oct. 23, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2014. In addition,
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal 2014 Financial Results
DUBLIN, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2014 on Thursday, October
Read more →TRIBTrinity Biotech Announces CE Marking of New Meritas Heart Failure (BNP) Point-of-Care Test
DUBLIN, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has obtained the CE mark (i.e. European approval) for its Meritas p
Read more →TRIBTrinity Biotech Announces Quarter 2 Financial Results; 25% Increase in Operating Profits
DUBLIN, July 29, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2014. Total revenues for Q2, 201
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2014 Financial Results
DUBLIN, July 21, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2014 on Tuesday, July 2
Read more →TRIBTrinity Biotech Announces Quarter 1 Results
Revenues Up 23%, Operating Profit Up 16% Increase in Dividend to 22 Cents DUBLIN, April 29, 2014 (GLOBE NEWSWIRE) --Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announ
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2014 Financial Results
DUBLIN, April 16, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2014 on Tuesday, April
Read more →TRIBTrinity Biotech Announces Results for Q4 and Fiscal Year 2013
DUBLIN, March 4, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for fiscal year 2013 and the quarter ended December 31, 2013. F
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2013 Financial Results
DUBLIN, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter fiscal year 2013 on Tuesday, March
Read more →TRIBTrinity Biotech Announces European Approval of Guideline Compliant, Point-of-Care, High Sensitivity Troponin I Product
DUBLIN, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Trinity Biotech plc. (Nasdaq:TRIB) today announced it has obtained the CE mark (i.e. European approval) for its Meritas, high sensitivity Troponin I (hsTnI) product. With its unrivalled precision, it is now the only point-of-care product
Read more →TRIBTrinity Biotech Announces Quarter 3 Financial Results, Acquisition of Blood Bank Screening Business and FDA Approval of HIV-2 Claim
DUBLIN, Ireland, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2013, the acquisiti
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2013 Financial Results
DUBLIN, Ireland, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2013 on Thursd
Read more →TRIBTrinity Biotech Announces Quarter 2 Financial Results and Acquisition of Immco Diagnostics Inc.
DUBLIN, Ireland, July 30, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2013 and the acquisition
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2013 Financial Results
DUBLIN, Ireland, July 23, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2013 on Tuesda
Read more →TRIBTrinity Biotech Announces Quarter 1 Results - EPS of 20 Cents, Premier Regulatory Approval in China and 33% Increase in Dividend to 20 Cents
DUBLIN, Ireland, April 25, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2013. Total revenues
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2013 Financial Results
DUBLIN, Ireland, April 16, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2013 on Thursd
Read more →TRIBTrinity Biotech Announces Results for Fiscal Year 2012
DUBLIN, Ireland, March 5, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point of care and clinical laboratory markets, today announced results for fiscal year 2012 and for the quarter ended December
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2012 Financial Results
DUBLIN, Ireland, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2012 on Tu
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2012 Financial Results
DUBLIN, Ireland, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter of fiscal year 2012 on Thurs
Read more →TRIBDear Shareholder You have received notification of an Extraordinary General Meeting of the Company to be held on Thursday
You have received notification of an Extraordinary General Meeting of the Company to be held on Thursday, September 27, 2012 at the Company s headquarters at IDA Business Park, Bray, Co.Wicklow. I would like to take this opportunity to outline the purpose of the meeting. At pre
Read more →TRIBTrinity Biotech Announces Quarter 2 Financial Results EPS of 20 Cents Per ADR -- an Increase of 11%
DUBLIN, Ireland, July 12, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2012. Total revenues fo
Read more →TRIBTrinity Biotech plc to Announce Second Quarter Fiscal Year 2012 Financial Results
DUBLIN, Ireland, July 5, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter of fiscal year 2012 on Thur
Read more →TRIBTrinity Biotech Added to Membership of Russell Global Index
DUBLIN, Ireland, June 26, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has been added as a member of the Russell Global Index as Ru
Read more →TRIBTrinity Biotech plc Announces Details of Its Dividend and Share Buyback Program
DUBLIN, Ireland, June 6, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced additional details of its Dividend and Share Buyback Program. At its
Read more →TRIBTrinity Biotech Announces an Annual Dividend of 15 Cents Per ADR -- an Increase of 50%
DUBLIN, Ireland, April 25, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced a proposed dividend of 15 cents per ADR. In 2011, Trinity ann
Read more →TRIBTrinity Biotech Announces Quarter 1 Financial Results
DUBLIN, April 19, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2012. Total revenues for Q1, 2
Read more →TRIBTrinity Biotech plc to Announce First Quarter Fiscal Year 2012 Financial Results
DUBLIN, April 10, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter of fiscal year 2012 on Thursday, Ap
Read more →TRIBTrinity Biotech Announces Quarter 4 Financial Results
DUBLIN, March 5, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2011. Total revenues for Q4,
Read more →TRIBTrinity Biotech plc Announces the Acquisition of Fiomi Diagnostics AB
DUBLIN, March 1, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced its acquisition of Fiomi Diagnostics AB for $13.1m (including $3.4m of c
Read more →TRIBTrinity Biotech Announces CE Marking of Rapid Test for Giardia
DUBLIN, Ireland, Feb. 28, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it had obtained CE Marking and has filed for FDA approval
Read more →TRIBTrinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2011 Financial Results
DUBLIN, Ireland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2011 on Mo
Read more →TRIBTrinity Biotech Announces FDA Approval of Premier Hb9210
DUBLIN, Ireland, Dec. 6, 2011 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has obtained FDA approval for the Premier Hb9210. The P
Read more →TRIBTrinity Biotech plc to Announce Third Quarter Fiscal Year 2011 Financial Results
DUBLIN, Ireland, Oct. 11, 2011 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter of fiscal year 2011 on Thur
Read more →TRIBTrinity BioGenics Acquires Lab and Intellectual Properties
CLEARWATER, Fla., April 3, 2006 (PRIMEZONE) -- Maui General Stores Inc. dba Trinity BioGenics Corp. (OTCBB:MAUG), a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with Immune Therapy, is pleased to announce that
Read more →TRIBTrinity Biotech Provides HiberGen Update
DUBLIN, Nov. 14, 2003 (PRIMEZONE) -- Trinity Biotech plc (Nasdaq:TRIB) today announced that the recent fundraising undertaken by HiberGen has not been successful. As a consequence, the Board of HiberGen has decided to cease trading with immediate effect. Trinity invested US$1.37
Read more →Competitive Position
How TRIB ranks across every disease it competes inCompetitive Position is a premium feature
See how TRIB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial